Issue Information
Inhibitor screening in non‐severe haemophilia patients; a major challenge
Acute megakaryoblastic leukaemia
Cryptococcosis in late stage multiple myeloma
Recent advances in T‐cell immunotherapy for haematological malignancies
Dawning of the age of genomics for platelet granule disorders
The future of academic haematology
Investigation and management of IgM and Waldenström‐associated peripheral neuropathies
Continuous treatment with lenalidomide and low‐dose dexamethasone in transplant‐ineligible patients with newly diagnosed multiple myeloma in Asia
The survival outcome of patients with relapsed/refractory peripheral T‐cell lymphoma‐not otherwise specified and angioimmunoblastic T‐cell lymphoma
RB but not R‐HCVAD is a feasible induction regimen prior to auto‐HCT in frontline MCL
Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2nd‐line therapy for relapsed and refractory multiple myeloma – a phase II trial
Phase 2 study of tabalumab, a human anti‐B‐cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma
Treatment burden, haemostatic strategies and real world inhibitor screening practice in non‐severe haemophilia A
Exacerbation of oxidative stress during sickle vaso‐occlusive crisis is associated with decreased anti‐band 3 autoantibodies rate and increased red blood cell‐derived microparticle level
Molecular typing for blood group antigens within 40 min by direct polymerase chain reaction from plasma or serum
To select or not to select? The role of B‐cell selection in determining the MYD88 mutation status in Waldenström Macroglobulinaemia
Rapid parallel acquisition of somatic mutations after NPM1 in acute myeloid leukaemia evolution
Ibrutinib monotherapy as effective treatment of central nervous system involvement by chronic lymphocytic leukaemia
Rituximab plus ABVD in newly diagnosed nodular lymphocyte‐predominant Hodgkin lymphoma
Heavy menstrual bleeding on Rivaroxaban ‐ Comparison with Apixaban